Abstract
Purpose
To determine the clinical effectiveness and potential neuroprotection of levodopa in improving visual acuity, visual field, and retinal nerve fiber layer (RNFL) thickness in eyes affected by NAION.
Method
Retrospective cohort study involving 59 eyes of 59 participants with NAION who were evaluated within 15 days of NAION onset. Participants received 25 mg carbidopa/100 mg levodopa three times daily with meals for 12 weeks (levodopa group) or were untreated (control group). Best-corrected visual acuity converted to logMAR, mean deviation (MD) threshold sensitivity on automated perimetry, and mean RNFL thickness on optical coherence tomography (OCT) were assessed. The primary outcome was the categorization of eyes into improved visual acuity (by 0.3 logMAR difference), worsened visual acuity (by 0.3 logMAR difference), or no change in visual acuity. The proportions in each category were compared between the levodopa and control groups.
Results
Among participants with 20/60 or worse initial visual acuity, levodopa-treated participants had significant improvement (P < 0.0001) in the mean change from initial to final logMAR visual acuity of −0.74 ± 0.56 (95 % CI, −0.98 to −0.50), while the mean change for the control group at −0.37 ± 1.09 (95 % confidence interval estimate, −1.00 to +0.26) was not significant (P = 0.23). A significant difference between groups was observed (P = 0.0086) such that 19/23 (83 %) in the levodopa group improved and none got worse, as compared with 6/14 (43 %) in the control group improving while four (29 %) worsened. The change in visual field MD and RNFL thickness on OCT showed no significant difference at P = 0.23 and P = 0.75 respectively. No levodopa-treated participant had any adverse event from the levodopa.
Conclusions
Treatment within 15 days of onset of NAION with levodopa improved central visual acuity by an average of 6 lines on Snellen acuity chart. Levodopa may promote neuroprotection of the maculopapular retinal ganglion cell fibers in NAION.
Similar content being viewed by others
References
Johnson LN, Arnold AC (1994) Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy: population-based study in the State of Missouri and Los Angeles County. J Neuro-Ophthalmol 14:38–44
Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT (1997) Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 123:103–107
The Ischemic Optic Neuropathy Decompression Trial (IONDT) Research Group (1995) Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful: results of the Ischemic Optic Neuropathy Decompression Trial. JAMA 273:625–632
Newman NJ, Scherer R, Langenberg P, Kelman S et al (2002) The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 134:317–328
Johnson LN (2003) Chlamydia pneumoniae Seropositivity and the risk of nonarteritic anterior ischemic optic neuropathy (NAION). Ophthalmology 110:1067–1069
Johnson LN (1998) Nonarteritic anterior ischemic optic neuropathy. J Am Optom Assoc 69:422–423
Johnson LN, Krohel GB, Allen SD, Mozayeni R (1996) Recurrent herpes labialis as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. J Natl Med Assoc 88:369–373
Johnson LN, Kuo HC, Arnold AC (1993) Human Leukocyte Antigen (HLA-A29) as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 115:540–541
Burde RM (1993) Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 116:759–764
Kerr NM, Chew SS, Danesh-Meyer HV (2009) Non-arteritic anterior ischaemic optic neuropathy: a review and update. J Clin Neurosci 16:994–1000
Mojon DS, Hedges TR 3rd, Ehrenberg B, Karam EZ et al (2002) Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 120:601–605
Beck RW, Servais GE, Hayreh SS (1987) Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 94:1503–1508
Deramo VA, Sergott RC, Augsburger JJ, Foroozan R et al (2003) Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology 110:1041–1046
Fry CL, Carter JE, Kanter MC et al (1993) Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke 24:539–542
Johnson LN, Botelho PJ, Kuo HC (1994) Is smoking a risk factor for NAION? Ophthalmology 101:1322–1324
Müller M, Wessel K, Mehdorn E, Kompf D et al (1993) Carotid artery disease in vascular ocular syndromes. J Clin Neuroophthalmol 13:175–180
Hayreh SS, Jonas JB, Zimmerman MB (2007) Nonarteritic anterior ischemic optic neuropathy and tobacco smoking. Ophthalmology 114:804–809
Knox DL, Kerrison JB, Green WR (2000) Histopathologic studies of ischemic optic neuropathy. Trans Am Ophthalmol Soc 98:203–222
Odette JD, Okorodudu DO, Johnson LN (2011) Early diabetes mellitus or hypertension is not significantly associated with severity of visual loss in nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 129:1106–1107
Botelho PJ, Johnson LN, Arnold AC (1996) The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 121:450–451
Aptel F, Khayi H, Pépin JL, Tamisier R et al (2015) Association of nonarteritic ischemic optic neuropathy with obstructive sleep apnea syndrome. Consequences for obstructive sleep apnea screening and treatment. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2015.0893, Published online April 30, 2015
Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL (1994) Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 117:603–624
Hayreh SS (2001) Blood flow in the optic nerve head and factors that may influence it. Prog Retin Eye Res 20:595–624
Levin LA, Louhab A (1996) Apoptosis of retinal ganglion cells in anterior ischemic optic neuropathy. Arch Ophthalmol 114:488–491
Nork TM, Kim CBY, Shanmuganayagam D, Van Lysel MS et al (2006) Measurement of regional choroidal blood flow in rabbits and monkeys using fluorescent microspheres. Arch Ophthalmol 124:860–868
Alm A, Bill A (1987) Ocular circulation. In: Moses RA, Hart WH Jr (eds) Adler’s physiology of the eye clinical application, 8th edn. Mosby, St. Louis, pp 183–203, Fig 6–11, pg 191
Parsa CF, Hoyt WF (2015) Nonarteritic anterior ischemic optic neuropathy (NAION): a misnomer. Rearranging pieces of a puzzle to reveal a nonischemic papillopathy caused by vitreous separation. Ophthalmology 122:439–442
Atkins EJ, Bruce BB, Newman NJ, Biousse V (2010) Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 55:47–63
Nicholson JD, Leiba H, Goldenberg-Cohen N (2014) Translational preclinical research may lead to improved medical management of non-arteritic anterior ischemic optic neuropathy. Front Neurol 5:1–5
Golan S, Waisbourd M, Kesler A (2011) Nonarteritic anterior ischemic optic neuropathy — an update. J Clin Exp Ophthalmol S3:001,1–10
Parisi V, Coppola G, Ziccardi L, Gallinaro G et al (2008) Cytidine-5′-diphosphocholine (citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol 15:465–474
Johnson LN, Gould TJ, Krohel GB (1996) Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months duration. Am J Ophthalmol 121:77–83
Johnson LN, Guy ME, Krohel GB, Madsen RW (2000) Levodopa may improve vision loss in recent onset nonarteritic anterior ischemic optic neuropathy. Ophthalmology 107:521–526
Johnson LN, Aminlari A, Sassani JW (1993) Effect of intermittent versus continuous patient monitoring on reliability indices during automated perimetry. Ophthalmology 100:76–84
Knight OJ, Chang RT, Feuer WJ, Budenz DL (2009) Comparison of retinal nerve fiber layer measurements using time domain and spectral domain optical coherent tomography. Ophthalmology 116:1271–1277
Contreras I, Noval S, Rebolleda G, Munoz-Negrete FJ (2007) Follow-up of nonarteritic anterior ischemic optic neuropathy with optical coherence tomography. Ophthalmology 114:2338–2344
Rebolleda G, Perez-Lopez M, Casas-Llera P, Contreras I et al (2013) Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefes Arch Clin Exp Ophthalmol 251:255–260
Bellusci C, Savini G, Carbonelli M, Carelli V et al (2008) Retinal nerve fiber layer thickness in nonarteritic anterior ischemic optic neuropathy: OCT characterization of the acute and resolving phases. Graefes Arch Clin Exp Ophthalmol 246:641–647
Razeghinejad MR, Rahat F, Bagheri M (2010) Levodopa-carbidopa may improve vision loss in indirect traumatic optic neuropathy. J Neurotrauma 27:1905–1909
Gottlob I, Stangler-Zuschrott E (1990) Effect of levodopa on contrast sensitivity and scotomas in human amblyopia. Invest Ophthalmol Vis Sci 31:776–780
Leguire LE, Rogers GL, Bremer DL, Walson PD et al (1993) Levodopa/carbidopa for childhood amblyopia. Invest Ophthalmol Vis Sci 34:3090–3095
Gottlob I, Charlier J, Reinecke RD (1992) Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 33:2722–2728
Repka MX, Kraker RT, Beck RW, Atkinson SC et al (2010) A pilot study of levodopa dosage as treatment for residual amblyopia in children 8 to <18 years old. Arch Ophthalmol 128:1215–1217
Pediatric Eye Disease Investigator Group (PEDIG), Repka MX, Kraker RT, Dean TW, Beck RW et al (2015) A randomized trial of levodopa as treatment for residual amblyopia in older children. Ophthalmology 122:874–881
Simsek T, Eryilmaz T, Acaroglu G (2005) Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. Int J Clin Pract 59:287–290
Ghanbari H, Dehghani A (2000) Levodopa plus carbidopa: is it effective in nonarteritic anterior ischemic optic neuropathy management? J Res Med Sci 5:60
Johnson LN, Harris Lyttle DP, Petroski GF (2014) Visual recovery and OCT changes following treatment of nonarteritic anterior ischemic optic neuropathy with levodopa, allopurinol and tetracycline. Invest Ophthalmol Vis Sci 55:6220
Levin LA (2007) Axonal loss and neuroprotection in optic neuropathies. Can J Ophthalmol 42:403–408
Mora-Ferrer C, Neumeyer C (2009) Neuropharmacology of vision in goldfish: a review. Vis Res 49:960–969
Ventura AL, de Mello FG, de Melo Reis RA (2013) Methods of dopamine research in retina cells. Methods Mol Biol 964:25–42
Vaarmann A, Kovac S, Holmström KM, Gandhi S et al (2013) Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis 4, e455
Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31:2473–2475
Yavas GF, Yilmaz O, Küsbeci T, Oztürk F (2007) The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 17:812–816
Kashii S, Takahashi M, Mandai M, Shimizu H et al (1994) Protective action of dopamine against glutamate neurotoxicity in the retina. Invest Ophthalmol Vis Sci 35:685–695
Olanow CW (2009) Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 72(Suppl2):S59–S64
Nair VD, Olanow CW, Sealfon SC (2003) Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373:25–32
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Research to Prevent Blindness, Inc. (New York, New York) provided financial support in part, in the form of an unrestricted grant to the Department of Ophthalmology at the University of Missouri–Columbia. The sponsor had no role in the design or conduct of this research.
Conflict of interest
All authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical approval
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards. For this type of study, formal consent was not required.
Rights and permissions
About this article
Cite this article
Lyttle, D.P., Johnson, L.N., Margolin, E.A. et al. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 254, 757–764 (2016). https://doi.org/10.1007/s00417-015-3191-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-015-3191-z